- Clinical Trials
- April 2024
- 115 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Report
- May 2022
- 240 Pages
Global
From €3171EUR$3,300USD£2,726GBP
- Report
- March 2020
- 330 Pages
Global
From €2883EUR$3,000USD£2,479GBP
- Report
- June 2020
- 753 Pages
Global
From €3171EUR$3,300USD£2,726GBP
- Report
- April 2020
- 113 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Report
- July 2021
- 50 Pages
China
From €2498EUR$2,600USD£2,148GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- November 2021
- 747 Pages
Global
From €3843EUR$4,000USD£3,305GBP
- Book
- February 2018
- 448 Pages
Temozolomide is an alkylating agent used in the treatment of certain types of cancer, most notably glioblastoma multiforme. It is a prodrug, which is converted in the body to its active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). Temozolomide is used in combination with radiation therapy to treat newly diagnosed glioblastoma multiforme, and as a single agent to treat recurrent glioblastoma multiforme. It is also used to treat anaplastic astrocytoma, a type of brain tumor.
Temozolomide is a generic drug, and is available in many countries. It is marketed by several companies, including Merck, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
